Ovid Therapeutics INC Schedule 13G passive stakes

ADAR1 Capital Management, LLC, along with related entities and individuals, has filed a Schedule 13G amendment indicating a reduction in their beneficial ownership of Ovid Therapeutics Inc. common stock to below 5%.

RA Capital Management and its affiliates now beneficially own 9.9% of Ovid Therapeutics' common stock, primarily through warrants and direct holdings, as of June 30, 2026.

Eventide Asset Management, LLC, along with individuals Finny Kuruvilla and Robin C. John, have reported beneficial ownership of 11,812,241 shares, representing 6.3% of Ovid Therapeutics Inc.'s common stock as of June 30, 2026.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 4.99% of Ovid Therapeutics Inc. common stock.

Federated Hermes, Inc. and related entities have filed a Schedule 13G, reporting beneficial ownership of 4.15% of Ovid Therapeutics Inc. common stock as of June 30, 2026.

Eventide Asset Management, LLC, along with individuals Finny Kuruvilla and Robin C. John, have reported beneficial ownership of 12,773,577 shares, representing 7.3% of Ovid Therapeutics Inc.'s common stock as of March 31, 2026.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Ovid Therapeutics Inc. common stock.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 5.33% of Ovid Therapeutics Inc. common stock.

Jeremy M. Levin has reported beneficial ownership of 8,551,502 shares, representing 4.5% of Ovid Therapeutics Inc.'s common stock as of March 31, 2026.

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 15,635,484 shares, representing 9.1% of Ovid Therapeutics Inc.'s common stock, as of March 31, 2026.

Affinity Asset Advisors, LLC and Michael Cho have disclosed a 9.0% beneficial ownership stake in Ovid Therapeutics Inc., including shares from warrants.

Federated Hermes, Inc. and related entities have reported a 5.94% beneficial ownership stake in Ovid Therapeutics Inc. common stock as of December 31, 2025.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has reported a 5.1% beneficial ownership stake in Ovid Therapeutics Inc.

RA Capital Management and its affiliates have reported a 9.9% beneficial ownership stake in Ovid Therapeutics Inc., including common stock and exercisable warrants.

Affinity Asset Advisors and Affinity Healthcare Fund have reported a 9.0% beneficial ownership stake in Ovid Therapeutics Inc., totaling 12,149,166 shares.

Takeda Pharmaceutical Company Limited and its subsidiary Takeda Pharmaceuticals U.S.A., Inc. reported an aggregate beneficial ownership of 12.3% in Ovid Therapeutics Inc. common stock.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in Ovid Therapeutics Inc., holding over 7.1 million shares.

Biotechnology Value Fund and its affiliated entities have filed an amended Schedule 13G, reporting a complete divestment of their beneficial ownership in Ovid Therapeutics Inc.

BlackRock, Inc. has reported a 1.9% beneficial ownership stake in Ovid Therapeutics Inc., holding 1,369,010 shares of common stock as of June 30, 2025.

Rubric Capital Management LP and David Rosen have filed an amended Schedule 13G, reporting a 0.67% passive beneficial ownership stake in Ovid Therapeutics Inc. as of June 30, 2025.

A group of investment entities, including Madison Avenue Partners, LP and Madison Avenue International LP, have disclosed an updated passive 4% beneficial ownership stake in Ovid Therapeutics Inc., holding 2,852,352 shares as of December 31, 2024.